Stryker Corporation · SYK · FY2025 Q4 · Calendar Q1 2026

Stryker pairs record growth with raised 2026 guidance

The call supports a constructive operating thesis: strong procedure volumes, Mako adoption, product launches, international expansion, and tuck-in M&A underpin raised 2026 guidance. That support is conditional, with tariffs, regulation, reimbursement, competition, and macro demand as material offsets.

Why did SYK rise 4.3% after beating EPS estimates in FY2025 Q4?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNYSEHealthcare $105.62B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $4.47 Consensus $4.40
EPS surprise +1.6% Reported versus consensus
Reported revenue $7.17B Consensus $7.12B
Revenue surprise +0.7% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move +4.3% Event window
SPY move -0.3% Same window
Abnormal move +4.6% Stock minus SPY
Volume 1.8× Versus trailing sessions
Subsequent drift +4.7% Up to 20 sessions
SYKSPY benchmark

Ask FN2 about SYK FY2025 Q4

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, management moved from a raised 2025 outlook to a raised 2026 outlook and emphasized a broader Mako pipeline, SmartCare expansion, AI productivity tools, and continued tuck-in M&A. The tariff exposure increased to an estimated $400 million for 2026, while the company still expects margin expansion.

Guidance delta

Management raised 2026 guidance to 8%–9.5% organic sales growth and adjusted EPS of $14.90–$15.10.

Key takeaways

  • 2025 organic sales grew 10.3% and full-year revenue topped $25 billion.
  • Mako installations exceeded 3,000 worldwide, with expanding applications and a handheld robot launch supporting the pipeline.
  • Management cited continued margin expansion despite an estimated $400 million 2026 tariff impact.
  • The reported quarter modestly exceeded consensus on EPS and revenue.
  • The main debate is whether innovation, procedure volumes, and M&A can offset tariff, regulatory, reimbursement, and macro risks.

Management priorities

  • Expand Mako applications and commercialize the handheld RPS robot for total knee.
  • Grow SmartCare, including Vocera and Care AI, and invest in AI tools for productivity.
  • Pursue tuck-in acquisitions and specialized sales-force expansion.
  • Advance international growth across South Korea, Japan, Australia/New Zealand, Canada, and emerging markets.

Follow SYK with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
SYK REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q2 '24 estimate $5B Q2 '24 actual $5B, beat Q3 '24 estimate $5B Q3 '24 actual $5B, beat Q2 '25 estimate $6B Q2 '25 actual $6B, beat Q3 '25 estimate $6B Q3 '25 actual $6B, beat Q4 '25 estimate $7B Q4 '25 actual $7B, beat Q1 '26 estimate $6B Q1 '26 actual $6B, miss Q2 '26 estimate $7B Q2 '26 actual $7B, beat Q3 '26 estimate $7B Q3 '26 actual $7B, miss Q4 '26 estimate $8B Q1 '27 estimate $7B
Show 2 more >

Analyst Consensus ?

ConsensusBuy52 ratings
Bullish3669.2%
Neutral1630.8%
Bearish00.0%

Analyst 52W Price Targets

$310Current
$260Low
$352.31Average
$465High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Piper Sandler Overweight OverweightMaintainNov 9, 2026
Truist Securities Hold HoldMaintainNov 2, 2026
Stifel Buy BuyMaintainNov 2, 2026
TD Cowen Hold HoldMaintainOct 30, 2026
RBC Capital Outperform OutperformMaintainOct 30, 2026
Show 47 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $310. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Stifel NicolausRick Wise$325$291.86 +4.8%Nov 2, 2026
BMO CapitalVik Chopra$309$296 -0.3%Oct 30, 2026
RBC CapitalShagun Singh$375$295.08 +21.0%Oct 30, 2026
Raymond JamesJayson Bedford$323$311.36 +4.2%Oct 30, 2026
CitizensDavid Turkaly$390$291.86 +25.8%Oct 30, 2026
See 98 more

Track every rating change on SYK the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items.…

Historical context

All SYK earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the SYK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
  3. Polygon adjusted daily market bars · 2026-10-01T03:56:07.683590+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T03:56:07.680737+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.